Compare Nomura Holdings Inc (NMR) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Nuwellis Inc — how do they compare? Nomura Holdings Inc trades at $9.49 (market cap $28.05B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Nomura Holdings Inc is far larger — about 12750× Nuwellis Inc's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 55 Days and Nuwellis Inc for 26 Days on average.
| NMR | NUWE | |
|---|---|---|
Market Cap | $28.05B | $2.20M |
Volume | 729,574 | 121,544 |
Sector | Financials | Health |
52-Week High | $10.86 | $146.65 |
52-Week Low | $6.73 | $0.68 |
Typical Hold Time | 55 Days | 26 Days |
Enterprise Value | $38.55T | -$1.52M |
Dividend Yield | 3.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.53, down 2.56% today amid bearish technical signals. The stock shows mixed fundamentals with strong revenue growth to $1.66T in 2025 and net income margin of 20.4%, but recent earnings misses and negative operating cash flow raise concerns. Valuation appears reasonable with P/E of 11.29 and P/B of 1.15. Analyst consensus leans cautious with 67% hold ratings despite recent Zacks strong buy recommendations.
NMR presents a value opportunity with attractive valuation multiples, though execution risks persist. The bearish technical trend and inconsistent earnings performance warrant caution. Upside potential exists if the company can sustain revenue growth and improve cash flow generation, but investors should monitor debt levels increasing to 26.25% of assets.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
